Results 1 to 10 of about 1,715 (181)

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus

Therapeutics and Clinical Risk Management, 2022
Ronak G Gandhi,1 Camille N Kotton2 1Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA; 2Infectious Diseases Division, Massachusetts General Hospital, Boston, MA, USACorrespondence: Ronak G Gandhi, Senior Attending Pharmacist ...
Ronak Gandhi, Camille Nelson Kotton
exaly   +6 more sources

Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients [PDF]

Viruses
Background: Human cytomegalovirus (CMV) remains an important pathogen, especially for immunocompromised patients such as solid organ and hematopoietic stem cell recipients. Viral genomic mutations conferring drug resistance are an important impediment to
Steven B. Kleiboeker
doaj   +4 more sources

Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients [PDF]

Drug Design, Development and Therapy
Raymund R Razonable1,2 1Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USACorrespondence ...
Raymund R Razonable
exaly   +4 more sources

Use of Maribavir in Adult Patients With Post-Transplant Refractory Cytomegalovirus Infection in the Real-Life Setting [PDF]

Transplant International
Maribavir is indicated for the treatment of refractory cytomegalovirus (CMV) infection/disease in patients who have undergone a solid organ transplant (SOT) or hematopoietic cell transplant (HCT).
Nassim Kamar, Fanny Vuotto, Catherine Cordonnier, Philippe Gatault, Faouzi Saliba, Faouzi Saliba, Lionel Couzi, Vincent Bunel, Vincent Bunel, Cinira Lefevre, Michèle Maric, Abdelkrim Ziad, Sophie Alain   +12 more
doaj   +2 more sources

Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis [PDF]

Transplant International
Cytomegalovirus (CMV) infection following solid organ transplant (SOT) is associated with increased mortality risk. In the phase 3 SOLSTICE study (NCT02931539), more transplant recipients achieved CMV clearance after 8 weeks with maribavir than ...
Nassim Kamar, Robin K. Avery, Tien Bo, Joan Gu, Deepali Kumar, Oliver Witzke   +5 more
doaj   +2 more sources

Evaluating valaciclovir, letermovir, and maribavir safety in first-trimester human placental development [PDF]

Scientific Reports
Congenital cytomegalovirus (CMV) infection is the leading preventable cause of childhood disability, including sensorineural hearing loss and cerebral palsy in high-income countries.
Ishara Atukorala, Natasha de Alwis, Sally Beard, Swetha Raghavan, Natalie J. Hannan, Lisa Hui   +5 more
doaj   +2 more sources

Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients With First Episode or Refractory Cytomegalovirus [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Maribavir's anti‐cytomegalovirus (CMV) activity and favorable safety/tolerability profile is a welcomed addition to the CMV treatment armamentarium.
Kefeng Sun, Claudia Jomphe, Nathalie H. Gosselin, Leon Pheng, Chandrasekar Durairaj, Yaming Hang, Indranil Bhattacharya   +6 more
doaj   +2 more sources

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundMaribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation.
Haolin Teng, Shengnan Zhang, Jinyu Yu, Faping Li   +3 more
doaj   +2 more sources

Case Report: Maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke’s immune-osseous dysplasia [PDF]

Frontiers in Immunology
Cytomegalovirus (CMV) is a major opportunistic pathogen in recipients of solid organ transplantation. Maribavir, a pUL97 protein kinase inhibitor, was approved for the treatment of refractory post-transplant CMV infection in the US in 2021.
Jia-Shuan Huang, Jia-Shuan Huang, Hong-Kai Wang, Li-Ping Rong, Xiao-Yun Jiang, Long-Shan Liu, Liu-Yi Huang, Na Zhang, Zhi-Hui Yue   +8 more
doaj   +2 more sources

Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-) [PDF]

Viruses
The emergence of drug-resistant cytomegalovirus (CMV) complicates viral response to therapy. We present two cases of solid organ transplant (SOT) recipients, highlighting the reversion of UL97 mutations associated with val(ganciclovir) resistance ...
Elena Seminari, Alessandra Tebaldi, Aurelia Sangani, Paola Giordani, Daniele Lilleri, Stefania Paolucci, Giulia Campanini, Elizabeth Iskandar, Fausto Baldanti, Raffaele Bruno   +9 more
doaj   +2 more sources